Investor Presentaiton
Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma
alnuctamab
GPRC5D
iber/mezi
Pivotal KarMMa-9 in patients with sub-optimal response
post-ASCT
Inclusion Criteria:
Adult patients with PR or
VGPR to ASCT
Primary Endpoint:
PFS
Key Secondary Endpoint:
•
OS
Stratification Factors:
R-ISS III at initial diagnosis
Anti-CD38 induction
•
VGPR vs PR
Ill Bristol Myers Squibb™
NDMM after
4-6 Cycles Induction
HDT/ASCT
PR or VGPR
lenalidomide
maintenance
1 cycle
R
1:1
Ide-cel
manufacturing
Apheresis
Flu/Cy +
ide-cel
lenalidomide
maintenance
(start 1 month after
ide-cel/counts recovery;
continue until PD)
lenalidomide maintenance until PD
Pivotal KarMMa-9 study initiating
Data anticipated in 2027
Follow-Up
Not for Product Promotional Use
84View entire presentation